1. Volume 128, Issue 3, Pages 764-770 (March 2005)
Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea 
Stavros Sougioultzis, Lorraine Kyne, Denise Drudy, Sarah Keates, Seema Maroo, Charalabos Pothoulakis, Paul J. Giannasca, Cynthia K. Lee, Michel Warny, Thomas P. Monath, Ciarán P. Kelly 
Gastroenterology 
Volume 128, Issue 3, Pages (March 2005)
DOI: /j.gastro
Copyright © 2005 American Gastroenterological Association Terms and Conditions

2. Figure 1
Serum IgG antitoxin A antibody values in 3 subjects with recurrent C difficile–associated diarrhea. The subjects received intramuscular inoculations of a C difficile toxin vaccine on days 0, 7, 28, and 56 (arrows). Serum IgG antitoxin A antibody was measured by ELISA. The highest dilutions of serum that neutralized the cytotoxicity of purified C difficile toxin A are shown in parentheses for all serum samples that had detectable toxin neutralizing activity.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

3. Figure 2
Serum IgG antitoxin B antibody values in 3 subjects with recurrent C difficile associated diarrhea. The subjects received intramuscular inoculations of a C difficile toxin vaccine on days 0, 7, 28, and 56 (arrows). Serum IgG antitoxin B antibody was measured by ELISA. The highest dilutions of serum that neutralized the cytotoxicity of purified C difficile toxin B are shown in parentheses for all serum samples that had detectable toxin neutralizing activity.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2005 American Gastroenterological Association Terms and Conditions